ClinicalTrials.gg
CompletedNCT07088913Updated Mar 3, 2026

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants

A Phase 1 interventional study of Capivasertib and Rosuvastatin in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of the study is to assess the effect of capivasertib on the pharmacokinetics (PK) of oral rosuvastatin in healthy participants.

Read the detailed description

This study is an open-label, fixed-sequence, drug-drug interaction study of orally administered rosuvastatin in the presence and absence of capivasertib in healthy participants.

The study will comprise:

  1. A Screening Period of maximum 28 days.
  2. Two Treatment Periods

    • Period 1: Participants will receive single oral dose of rosuvastatin.
    • Period 2: Participants will receive two single oral doses of capivasertib administered 12 hours apart, with the first capivasertib dose being concomitantly administered with a single oral dose of rosuvastatin.
  3. A final Follow-up Visit within 7 to 10 days after the last study intervention administration.

There will be a minimum washout period of at least 7 days between the first dose of rosuvastatin (in Treatment Period 1) and the second dose of rosuvastatin (in Treatment Period 2).

02

Conditions studied

  • Healthy Participants

Keywords

  • Drug-drug interaction
  • Pharmacokinetics
  • Breast Cancer Resistance Protein
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Healthy male and/or female participants with suitable veins for cannulation or repeated venipuncture.
  2. (BMI) between 18 and 32 kg/m² inclusive and weigh at least 50 kg and no more than 150 kg inclusive.
  3. All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit and must not be lactating.
  4. Females of non- must be confirmed at the Screening Visit by fulfilling one of the following criteria:

    1. (≥12 months of amenorrhea + hormone confirmation).
    2. Irreversible surgical sterilization by hysterectomy and/or bilateral oophorectomy, and/or bilateral salpingectomy (excluding tubal ligation) at least 6 months prior to screening.
  5. Male participants must be vasectomized (at least 6 months prior to screening), with documented post-procedural medical assessment of surgical success.
  6. Participants must be willing to use study-specific methods.

Key Exclusion Criteria:

  1. History of any disease or disorder which may either put the participant at risk because of participation in the study or influence the results or the participant's ability to participate in the study.
  2. History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically important illness, medical/surgical procedure, or trauma.
  4. Any clinically significant skin abnormalities that are chronic or currently active.
  5. Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results.
  6. Any positive result on screening for serum surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), virus antibody (HCV antibody), or (HIV).
  7. Any clinically significant abnormalities in blood lipid profiles (triglycerides, high-density lipoprotein, low-density lipoprotein, and total cholesterol).
  8. Any clinically significant abnormalities in glucose metabolism, including:

    1. Diagnosis of type I or II diabetes mellitus (irrespective of management),
    2. Fasting blood glucose ≥ 100 mg/dL, or
    3. > 5.7% after at least 8 hours of fasting at screening.
  9. Any clinically significant abnormal findings in vital signs.
  10. Any clinically significant abnormalities on 12-lead (ECG) and defined as Sick sinus syndrome, arrhythmia, prolonged > 450 ms, family history of long QT syndrome, persistent or intermittent bundle branch block, and atrio-ventricular block Grade II or III.
  11. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the previous 3 months.
  12. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
  13. History of severe allergy/ or ongoing clinically important allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to capivasertib or rosuvastatin or history of hypersensitivity to any component of the finished dosage form of capivasertib.
  14. Plasma donation or any blood donation/blood loss prior to the Screening Visit.
  15. Participants who have previously received capivasertib.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Rosuvastatin/Capivasertib+Rosuvastatin

    Participants will receive a single dose of rosuvastatin in Period 1. After a minimum washout period of 7 days from the first dose of rosuvastatin, participants will receive the first dose of capivasertib, administered concomitantly with a single dose of rosuvastatin in Period 2, followed by a second dose of capivasertib after 12 hours.

    Drug: Capivasertib · Drug: Rosuvastatin

Interventions

  • Capivasertib will be administered orally twice in Period 2.

    Also known as: AZD5363

  • Rosuvastatin will be administered orally once in both Period 1 and Period 2.

    Also known as: CRESTOR

06

What researchers measure

Primary outcomes

  1. Area under concentration-time curve from time 0 to infinity (AUCinf) of rosuvastatin

    To evaluate the PK (AUCinf) of rosuvastatin when administered orally alone and in combination with capivasertib.

    Time frame: Period 1: Day 1 to Day 3 and Period 2: Day 1 to Day 3

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of rosuvastatin

    To evaluate the PK (AUClast) of rosuvastatin when administered orally alone and in combination with capivasertib.

    Time frame: Period 1: Day 1 to Day 3 and Period 2: Day 1 to Day 3

  3. Maximum observed drug concentration (Cmax) of rosuvastatin

    To evaluate the PK (Cmax) of rosuvastatin when administered orally alone and in combination with capivasertib.

    Time frame: Period 1: Day 1 to Day 3 and Period 2: Day 1 to Day 3

Secondary outcomes

  1. Ratio of AUCinf (R AUCinf) of rosuvastatin

    To evaluate the PK (R AUCinf) of rosuvastatin when administered orally alone and in combination with capivasertib.

    Time frame: Period 1: Day 1 to Day 3 and Period 2: Day 1 to Day 3

  2. Ratio of AUClast (R AUClast) of rosuvastatin

    To evaluate the PK (R AUClast) of rosuvastatin when administered orally alone and in combination with capivasertib.

    Time frame: Period 1: Day 1 to Day 3 and Period 2: Day 1 to Day 3

  3. Ratio of Cmax (R Cmax) of rosuvastatin

    To evaluate the PK (R Cmax) of rosuvastatin when administered orally alone and in combination with capivasertib.

    Time frame: Period 1: Day 1 to Day 3 and Period 2: Day 1 to Day 3

  4. Terminal elimination half-life (t½λz) of rosuvastatin

    To evaluate the PK (t½λz) of rosuvastatin when administered orally alone and in combination with capivasertib.

    Time frame: Period 1: Day 1 to Day 3 and Period 2: Day 1 to Day 3

  5. Terminal elimination rate constant (λz) of rosuvastatin

    To evaluate the PK (λz) of rosuvastatin when administered orally alone and in combination with capivasertib.

    Time frame: Period 1: Day 1 to Day 3 and Period 2: Day 1 to Day 3

  6. Time to reach maximum observed concentration (tmax) of rosuvastatin

    To evaluate the PK (tmax) of rosuvastatin when administered orally alone and in combination with capivasertib.

    Time frame: Period 1: Day 1 to Day 3 and Period 2: Day 1 to Day 3

  7. AUClast of capivasertib

    To evaluate the PK (AUClast) of capivasertib following oral dosing.

    Time frame: Period 2: Day 1 to Day 3

  8. Concentration at the end of a dosing interval (Ctrough) of capivasertib

    To evaluate the PK (Ctrough) of capivasertib following oral dosing.

    Time frame: Period 2: Day 1 to Day 3

  9. Cmax of capivasertib

    To evaluate the PK (Cmax) of capivasertib following oral dosing.

    Time frame: Period 2: Day 1 to Day 3

  10. Number of participants with adverse events (AEs) and serious AEs

    To assess the safety and tolerability of capivasertib when administered with rosuvastatin.

    Time frame: From Screening (Day -30 to Day -2) to follow-up visit (Day 10)

  11. Change in serum bilirubin levels

    To evaluate the effect of capivasertib dosing on total, conjugated, and unconjugated bilirubin levels.

    Time frame: Day 1 (pre-capivasertib dose) to Day 3 (post-capivasertib dose)

07

Study locations

1 site
  • Research Site
    Baltimore, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Feb 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2025
First posted
Jul 28, 2025
StartActual
Jul 28, 2025
Primary completionActual
Feb 20, 2026
CompletionActual
Feb 20, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07088913
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jul 28, 2025
Start date
Jul 28, 2025
Primary completion
Feb 20, 2026
Completion
Feb 20, 2026
Last update
Mar 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capivasertib · Rosuvastatin

Start the discussion